DM Tests
Physiological Regulation of Blood Glucose Homeostasis
Blood glucose concentration is maintained within a narrow physiological range of () in healthy individuals.
Deviations from this homeostatic range are categorized as:
Hyperglycaemia: Blood glucose elevation above the normal physiological threshold.
Hypoglycaemia: Blood glucose drop below the normal physiological threshold.
Maintenance of blood glucose levels depends on the balance between glucose entry into the circulation and glucose removal by tissues:
Sources of circulating glucose:
Diet: Ingestion, enzymatic digestion, and intestinal absorption of carbohydrates.
Hepatic glycogenolysis: Breakdown of stored liver glycogen into free glucose; serves as the primary endogenous glucose source during early fasting periods ().
Gluconeogenesis: De novo synthesis of glucose from non-carbohydrate substrates including lactate, glycerol, and glucogenic amino acids (predominantly alanine); serves as the main endogenous glucose source during prolonged fasting or starvation ().
Fates and utilization of circulating glucose:
Energy production: Cellular uptake and metabolic oxidation (glycolysis, tricarboxylic acid cycle, and oxidative phosphorylation).
Storage: Conversion to glycogen via glycogenesis in the liver and skeletal muscle, and conversion to fatty acids/triacylglycerols via lipogenesis in adipose tissue.
Endocrine regulation of glucose balance:
High blood glucose state (postprandial):
Pancreatic beta-cells stimulate insulin secretion.
Insulin promotes peripheral glucose uptake in skeletal muscle and adipose tissue.
Insulin enhances hepatic glycogenesis.
Insulin suppresses hepatic gluconeogenesis.
Net effect: Blood glucose decreases toward the normal range ( or ).
Low blood glucose state (fasting/sleep):
Pancreatic alpha-cells stimulate glucagon secretion.
Glucagon stimulates hepatic glycogenolysis.
Glucagon stimulates hepatic gluconeogenesis.
Net effect: Blood glucose increases toward the normal homeostatic range.

Overview and Classification of Diabetes Mellitus
Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycaemia secondary to defects in insulin secretion, insulin action, or both.
Chronic hyperglycaemia results in widespread long-term structural and functional organ damage, dysfunction, and failure.
Clinical sequelae and complications:
Diabetic retinopathy (leading cause of adult blindness).
Diabetic nephropathy (leading cause of end-stage renal disease).
Cardiovascular disease (myocardial infarction and stroke).
Diabetic neuropathy and peripheral vascular disease (leading causes of non-traumatic lower limb amputation).
Clinical classifications of diabetes:
Type 1 Diabetes Mellitus (T1DM):
Previously termed insulin-dependent diabetes mellitus (IDDM) or juvenile/childhood-onset diabetes.
Characterized by deficient insulin production resulting from autoimmune destruction of pancreatic beta-cells.
Absolute requirement for exogenous insulin therapy for survival.
Type 2 Diabetes Mellitus (T2DM):
Previously termed non-insulin-dependent diabetes mellitus (NIDDM) or adult-onset diabetes.
Characterized by peripheral insulin resistance paired with a progressive relative defect in insulin secretion.
Gestational Diabetes Mellitus (GDM):
Any degree of glucose intolerance with onset or first recognition during pregnancy.
Blood glucose values are elevated above normal physiological levels but below established diagnostic thresholds for overt diabetes.
Other specific types of diabetes mellitus:
Genetic defects in beta-cell function (e.g., MODY) or insulin action.
Diseases of the exocrine pancreas (pancreatitis, trauma, pancreatectomy, neoplasia, cystic fibrosis, hemochromatosis).
Endocrinopathies (Cushing syndrome, acromegaly, pheochromocytoma, glucagonoma, hyperthyroidism).
Drug- or chemical-induced diabetes: Glucocorticoids (prednisolone), antipsychotic medications (typical agents like haloperidol and chlorpromazine, as well as newer atypical antipsychotics).
Prediabetes:
Characterized by intermediate hyperglycaemia manifesting as Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT).
Not classified as a discrete disease entity, but represents a major risk state for developing overt Type 2 diabetes and cardiovascular disease.
Strongly associated with obesity, dyslipidemia (elevated triglycerides, reduced HDL), hypertension, and metabolic syndrome.
Risk Factors for Developing Diabetes Mellitus
Advancing age.
Metabolic syndrome components.
Documented history of impaired fasting glucose (IFG) or impaired glucose tolerance (IGT).
Polycystic ovary syndrome (PCOS).
History of gestational diabetes mellitus (GDM) or delivery of a macrosomic infant weighing over .
Strong family history of diabetes mellitus (first-degree relatives).
Physical inactivity and sedentary lifestyle.
Established personal history of cardiovascular disease (CVD).
Elevated Body Mass Index (, or in Asian Americans).
Central (visceral/abdominal) obesity.
Systemic hypertension.
Abnormal serum lipid profile (hypertriglyceridemia, low HDL-cholesterol).
Elevated liver function tests (LFTs), often reflecting non-alcoholic fatty liver disease.
Pharmacotherapy with diabetogenic agents, including steroids (prednisolone) and antipsychotics (haloperidol, chlorpromazine, and atypical antipsychotics).
Fasting Blood Glucose (FBG) Test
Biochemical basis:
Reflects the homeostatic equilibrium between hepatic glucose production () and peripheral glucose disposal during the fasting state.
Mathematically represented as:
During the overnight fast, low circulating insulin combined with elevated glucagon drives hepatic glucose output via glycogenolysis and gluconeogenesis (utilizing alanine, other glucogenic amino acids, lactate, and glycerol).
Constant glucose utilization persists unabated in obligate glucose-dependent tissues (the brain, erythrocytes, and renal medulla).
Patient preparation protocol:
Complete fasting duration of (absolute minimum requirement of ).
Nutritional stability: Patient must consume a balanced diet containing typical daily carbohydrate requirements for at least prior to specimen collection.
Pharmacological washout: Patient must avoid drugs known to modulate glucose metabolism for at least prior to testing.
Diagnostic reference intervals:
Normal: .
Prediabetes (Impaired Fasting Glucose): .
Diabetes Mellitus: .

Random Blood Glucose (RBG) Test
Biochemical basis:
Evaluates instantaneous glycaemic status and metabolic homeostasis without restriction on previous caloric intake.
Captures the real-time balance between circulating glucose inputs (dietary absorption, ongoing hepatic glycogenolysis, and gluconeogenesis) and circulatory clearance (insulin-mediated uptake into muscle and adipocytes, insulin-independent neural uptake, glycogenesis, and cellular oxidation).
Clinical testing parameters:
Specimen collection occurs at any time of day, entirely independent of the timing or content of the previous meal.
Reflects short-term glycaemic equilibrium and acute homeostatic regulatory capacity.
Diagnostic reference intervals:
Normal: ().
Prediabetes: ().
Diabetes Mellitus: ().
Oral Glucose Tolerance Test (OGTT)
Clinical indications:
Diagnostic evaluation of non-pregnant adults exhibiting impaired fasting glucose.
Universal or risk-stratified screening of pregnant women between of gestation.
Assessment of functional physiological handling of a standard oral glucose challenge.
Standard procedure:
Patient observes an overnight fast lasting .
A baseline fasting venous blood sample is drawn for plasma glucose measurement.
The patient consumes a standardized oral glucose challenge consisting of of anhydrous glucose dissolved in water (glucose syrup) within .
A subsequent venous blood sample is drawn exactly post-ingestion.
Diagnostic cut-off values ( post-challenge):
Normal glucose tolerance: ().
Prediabetes (Impaired Glucose Tolerance): ().
Diabetes Mellitus: ().

Morphological interpretation of OGTT curves:
Normal response curve:
Fasting plasma glucose is within normal limits ().
Peak plasma glucose concentration occurs within the first hour ().
The peak concentration does not breach the renal tubular threshold for glucose ().
Plasma glucose declines rapidly, returning to baseline fasting levels by .
Urinalysis specimens collected concurrently show total absence of glucose and ketone bodies.
Diabetic curve (moderate to severe diabetes mellitus):
Fasting glucose is markedly elevated ().
The peak glucose level is delayed, appearing between post-load.
Peak glucose concentration significantly exceeds the physiological renal threshold ().
Blood glucose remains sustained and fails to return to baseline fasting concentrations within .
Glucosuria is present in urine aliquots, except in select cases of advanced chronic diabetic nephropathy or chronic nephritis presenting with an abnormally elevated renal threshold.
LAG curve (oxyhyperglycaemia):
Fasting baseline glucose is entirely normal.
Extremely rapid gastrointestinal absorption causes an exaggerated early spike within , exceeding the renal threshold () and producing transient glucosuria.
Subsequent insulin hypersecretion precipitates a rapid and complete descent back to baseline fasting concentrations or below by .
Etiologies: Hyperthyroidism, post-gastrectomy or post-gastroenterostomy states (accelerated gastric emptying), normal pregnancy, and very early-stage diabetes mellitus.
Renal glucosuria curve:
Plasma glucose trajectory remains completely normal throughout fasting, peak, and recovery phases.
Glucose appears in the urine due to a primary reduction in the tubular transport maximum for glucose reabsorption (), establishing an abnormally low renal threshold.
Postprandial Blood Glucose (PPBG) Test
Biochemical and clinical basis:
Evaluates peripheral post-challenge glucose handling and postprandial insulin secretory dynamics in response to mixed physiological meals.
In healthy individuals, endogenous insulin secretions normalize blood glucose levels within .
In diabetic individuals, impaired early-phase insulin release and peripheral insulin resistance result in protracted hyperglycaemic excursions.
Testing protocol:
Plasma glucose concentration is quantified exactly after consuming a standard meal.
Serves as an established clinical tool for monitoring glycemic management in patients with known diabetes and detecting postprandial hyperglycaemia.
Diagnostic reference intervals ( postprandial):
Normal: ().
Impaired Glucose Tolerance (Prediabetes): ().
Diabetes Mellitus: ().

Glycated Haemoglobin ()
Biochemical mechanism:
Mediated by a slow, non-enzymatic, irreversible condensation reaction (Amadori rearrangement) between free glucose molecules and the N-terminal valine residue of the haemoglobin beta-chain.
Occurs continuously within erythrocytes throughout their circulating lifespan ().
The final rate and degree of glycation are directly proportional to the ambient plasma glucose concentration and the temporal duration of erythrocyte exposure.
Clinical utility:
Serves as an objective index of mean integrated glycaemic concentration over the preceding ().
Utilized for the definitive diagnosis of diabetes and routine longitudinal monitoring of long-term glycaemic management.
Requires standard peripheral venous blood collection; requires no patient fasting, caloric restriction, or specific acute preparation.

Diagnostic reference cut-offs:
Normal: .
Intermediate hyperglycaemia (Prediabetes): .
Diabetes Mellitus: .
Laboratory analytical methodologies:
High-Performance Liquid Chromatography (HPLC): Highest precision and accuracy; considered the analytical gold standard.
Immunoassays: Highly common in clinical laboratories and point-of-care testing systems.
Electrophoresis or Enzymatic Assays: Less common alternative laboratory methods.
Confounding clinical factors and analytical limitations:
Falsely elevated readings:
Vitamin B12 deficiency anaemia.
Iron deficiency anaemia (delayed erythrocyte turnover).
Post-splenectomy states (prolonged erythrocyte survival).
Chronic kidney disease.
Chronic alcohol use disorder.
Normal pregnancy.
Falsely depressed readings:
Acute or severe chronic blood loss (hemorrhage).
Chronic liver disease.
Exogenous erythropoietin administration (reticulocytosis/young red cell population).
Variable or unpredictable effects (falsely increased or decreased):
Haemoglobinopathies (e.g., HbS, HbC, HbE traits or thalassemias).
Diagnostic Confirmation and Screening Protocols
Criteria for confirming a diagnosis of diabetes:
In asymptomatic individuals: Two separate abnormal test results obtained from different occasions are mandatory for definitive diagnosis. This requires either repeating the identical test on a new blood sample without delay or performing an alternative validated diagnostic test.
In symptomatic individuals: A single abnormal test result is sufficient for diagnosis in the presence of classical symptoms of hyperglycaemia (polyuria, polydipsia, unexplained weight loss) accompanied by a random plasma glucose ().
Screening protocols in asymptomatic adults:
Risk-based screening: Adults of any age who are overweight or obese (, or in individuals of Asian American descent) presenting with one or more additional diabetes risk factors.
Universal screening: All individuals, regardless of risk profiles, should begin routine screening at age .
Retesting interval: If screening results are within normal limits, repeat testing is recommended at a minimum interval of every .
Screening modalities: Fasting plasma glucose, plasma glucose during a OGTT, and possess equal diagnostic appropriateness.
Cardiovascular management: When prediabetes or diabetes is identified, evaluate and aggressively manage comorbid cardiovascular disease risk factors.
Screening protocols in children and adolescents:
Screen asymptomatic children and adolescents following the onset of puberty or after age who are overweight or obese ( percentile for age and sex, weight-for-height percentile, or weight of ideal for height) combined with additional risk factors (maternal history of GDM, family history of T2DM, race/ethnicity, signs of insulin resistance).
Diagnostic approach for acute Type 1 Diabetes Mellitus:
In patients exhibiting acute clinical presentations of hyperglycaemia, fasting or random plasma glucose tests are preferred over due to the rapid timeline of beta-cell loss.
Supporting diagnostics include evaluation of urinary glucose, urinary ketone bodies (acetoacetate), and quantification of pancreatic autoantibody panels (anti-GAD65, anti-IA-2, anti-insulin, and anti-ZnT8 autoantibodies).
Gestational Diabetes Mellitus (GDM)
Definition: Glucose intolerance of varying severity with initial onset or first clinical recognition occurring during pregnancy.
Maternal and fetal clinical risks:
Maternal risks: Preeclampsia, cesarean delivery, and increased long-term risk of developing permanent Type 2 diabetes postpartum.
Fetal and neonatal consequences:
Maternal hyperglycaemia results in persistent transplacental glucose transfer.
Fetal hyperglycaemia triggers compensatory pancreatic hypertrophy and fetal hyperinsulinemia.
Fetal hyperinsulinism drives excessive tissue growth and fat deposition, causing fetal macrosomia (birth weight ).
Postnatal acute neonatal hypoglycaemia caused by persistent neonatal hyperinsulinemia upon cessation of maternal glucose supply via the umbilical cord.
Increased lifetime risk for developing childhood obesity and Type 2 diabetes in adult life.

Clinical screening timeline and risk stratification:
High-risk pregnant women must be screened at their first prenatal visit:
Marked obesity.
Documented history of GDM in a previous pregnancy.
Presence of glycosuria.
Recurrent candidal vaginitis.
Strong family history of diabetes mellitus.
If initial early screening is negative, re-test between and of gestation.
Diagnostic thresholds in early pregnancy:
Fasting plasma glucose: ().
Random plasma glucose: ().
Diagnostic testing regimens for GDM:
One-step OGTT (fasting, , and measurements):
Fasting threshold: .
threshold: .
threshold: .
Two-step protocol with OGTT (fasting, , , and measurements):
Fasting threshold: .
threshold: .
threshold: .
threshold: .
Screening glucose challenge test (GCT):
Non-fasting administration of oral glucose load with plasma glucose measured at .
A result () warrants diagnostic progression to a formal multi-hour OGTT.
Postpartum follow-up recommendations:
Women diagnosed with GDM require lifelong screening for diabetes or prediabetes at least every .
Women with previous GDM identified with prediabetes must receive structured lifestyle modifications or pharmacological intervention (metformin) to mitigate Type 2 diabetes development.
Ancillary Laboratory Investigations
Serum Fructosamine:
Quantifies total glycated serum proteins, predominantly glycated serum albumin.
Because albumin has a biological circulating half-life of approximately (), fructosamine reflects mean glycaemic exposure across the preceding .
Serves as a validated clinical alternative to whenever red blood cell dynamics interfere with haemoglobin glycation, including:
Haemoglobinopathies.
Pregnancy (due to physiological plasma volume expansion and altered red cell turnover).
Advanced renal disease.
Analytical limitation: Results are dependent on baseline serum protein status; variations in serum albumin (e.g., hypoalbuminemia in nephrotic syndrome or cirrhosis) alter fructosamine measurements.
C-Peptide (Connecting Peptide):
A 31-amino-acid peptide cleaved from proinsulin in equimolar concentrations to mature insulin during packaging into beta